+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID07401537

Comparing Extended-Interval and Standard-Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-02-10

416

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Triple-negative breast cancer TNBC is a type of breast cancer that lacks certain receptors and does not respond well to endocrine therapy or anti-HER2 treatments. Researchers are studying an immunotherapy approach for advanced TNBC, focusing on patients who have responded to initial combination treatments. The study aims to find out if extending the time between immunotherapy doses can maintain treatment effectiveness while reducing side effects and improving quality of life. The trial compares two immunotherapy dosing schedules during the maintenance phase one group receives PD-1 inhibitors every 6 weeks at a fixed dose, while the other group receives the same dose every 3 weeks. Both groups continue to receive chemotherapy or TROP2-ADC drugs at standard intervals. This multicenter randomized study evaluates the safety and effectiveness of these dosing strategies for advanced TNBC patients who showed disease control after initial treatment. Participants will be monitored for progression-free survival up to 2 years and overall survival up to 3 years. Researchers will assess quality of life through questionnaires and track adverse events and treatment costs over 3 years. Study visits include evaluations of tumor response, organ function, and patient well-being. The trial starts with a screening, randomization, and treatment phases, followed by long-term follow-up for outcomes and safety.

CONDITIONS

Brief Title

Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

Research Team

J

Jieqiong Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here